Orthomolecular Solutions to Heart Disease
The following simple solution to prevent heart disease is currently ignored in favour of paradigm of more invasive and lucrative disease management. Studying the the data below, one could conclude that the eradication of the this disease has been known for some time but is simply being ignored. This is an update to a note I sent to a number of people who wanted to know about some inexpensive non drug solutions. This note is by no means complete as I have not covered herbal and other mineral adjuncts. So far - 5 people. that I know, have tired vitamin C and Lysine and have had very good results.
This type of empowered and cost effective disease prevention is becoming a real threat to the medical industry thus the CODEX initiative. Again, at the risk of boring the reader, I direct you to the following link and encourage you to educate as many people as possible on this imminent loss of safe health solutions and our freedoms. http://www.iahf.com/anh_lawsuit.html
1) Linus Pauling Therapy for Heart Disease is at http://www.paulingtherapy.com/ and copiously describes a non toxic, cost effective Orthomolecular approach using vitamin C and amino acids Lysine and Proline.
16] According to the Pauling/Rath 1994 United States patent, the amino acid lysine (lysine analogs), along with vitamin C and other antioxidants (e.g. Co-Q10, vitamin E and vitamin A), can, in sufficient concentration, inhibit Lp(a) binding to exposed lysine residues. Proline residues are also exposed by lesions in blood vessels. Later experiments showed that proline as well as lysine, with vitamin C, other amino acids and antioxidants, in oral amounts well past what is needed for prevention, becomes a solvent by inhibiting the binding of Lp(a). A binding inhibitor augmented with vitamin C can stop and apparently even reverses some plaque formations. Pauling and Rath even have a second U. S. patent for using these binding inhibitors as solvents to melt atherosclerotic plaques from human organs during organ transplants. The organ is dipped in the Lp(a) Binding Inhibitor solution and the plaques melt away.
U. S. Patent # 5,278,189 is for the prevention and treatment of occlusive cardiovascular disease with vitamin C and substances that inhibit the binding of lipoprotein-(a).
See also patent 5,230,996 .
Backing this up with Vitamin B6 is described in the Joe Hattersley paper "Vitamin B6: The overlooked Key to preventing heart attacks" More supporting data in response to my earlier email also has been included at the end of this note
ABSTRACT: Vitamin B6 (pyridoxine) opens the door to eliminating the 20th century's epidemic of heart attacks, cardiac arrests and strokes. Although shunned by the researchers who receive the bulk of heart disease research funding, it is creating excitement among a growing number of investigators. In this article relevant bits of B6's history are presented to show how it can prevent heart attacks with almost no side effects from moderate amounts. This article will also integrate the effects of vitamin B6 deficiency with Mathias Rath and Linus Pauling's theory (blaming heart attacks on deficient vitamin C and excess Lp(a) and Bruce Lipton's histamine theory into a general theory of atherogenesis.
As usual any effective products such as amino acids (mentioned below) which are very effective for many diseases and essentially non toxic (far less toxic than even salt) are banned illegally by Health Canada to protect their pharmaceutical friends! So you will have get them from the states - 250 (500 mg) tablets of lysine are available for approx $5 from US Walmart stores. The underground cost in Canada is over $50 courtesy of Health Canada.
Reduction of Lipoprotein(a) in Postmenopausal Women
As a general surgeon who is interested in the prevention of postmenopausal heart disease and in particular in the reduction of lipoprotein(a) [Lp(a)], I read with great interest the recent review by Dr Mosca1 regarding the role of HRT. Rapid progression of arteriographically determined coronary artery disease has been significantly more common in subjects with Lp(a) levels higher than 25 mg/dL.2 Approximately 33% of the population have elevated levels of Lp(a) (>25 mg/dL), a condition that is an independent risk factor for coronary artery disease.3, 4 The treatment currently recommended for postmenopausal women with Lp(a) levels higher than 25 mg/dL consists of a combination of HRT and niacin.4 The adverse effects of niacin use are flushing, headache, and liver dysfunction. I am a 53-year-old woman with a significantly elevated level of Lp(a) (27 mg/dL), but I found that I had to stop taking niacin primarily because of headaches. Thus, after a thorough review of the literature, I began to follow the advice of Linus Pauling. For individuals who have an Lp(a) level higher than 25 mg/dL and a family history of heart disease, the recommendation is to take 3 g/d of both ascorbic acid and L-lysine monohydrochloride.5 After 6 months of this regimen, with no adverse effects, my Lp(a) level decreased to 14 mg/dL, a reduction of 48%. The Lp(a) testing was done by the highly reliable Lawrence Berkeley National Laboratory/Berkeley HeartLab Department Technology Transfer program. The theory is that lysine is an Lp(a)-binding inhibitor and thus blocks the Lp(a) attachment to the arterial blood vessel wall and that ascorbic acid helps to repair the collagen injury to the blood vessel and acts as an antioxidant.5-7 Currently, pilot studies are being conducted on the Pauling therapy of elevated levels of Lp(a).
Kathie M. Dalessandri, MS, MD
Point Reyes Station, Calif
1. Mosca L. The role of hormone replacement therapy in the prevention of postmenopausal heart disease. Arch Intern Med. 2000;60:2263-2272.
2. Terres W, Tatsis E, Pfalzer B, Beil FU, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation. 1995;91:948-950. MEDLINE
3. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA. 1996;276:544-548. MEDLINE
4. Superko HR. Did grandma give you heart disease? the new battle against coronary artery disease. Am J Cardiol. 1998;82:34Q-46Q. MEDLINE
5. Pauling L, Rath M. Solution to the puzzle of human cardiovascular disease: its primary cause is ascorbate deficiency leading to the deposition of lipoprotein(a) and fibrinogen/fibrin in the vascular wall. J Orthomol Med. 1992;6:125-133.
6. Rath M, Pauling L. Hypothesis: lipoprotein(a) is a surrogate for ascorbate. Proc Natl Acad Sci U S A. 1990;87:6204-6207. MEDLINE
7. Pauling L. The Last Interview [videotape]. Lisle, Ill: Intellisoft Multimedia Inc; 1994.
(Arch Intern Med. March 12, 2001;161:772-773,)
Reduction of Lipoprotein(a) in Postmenopausal Women
In response to the above Joe wrote
Date: Fri, 30 May 2003 13:18:52 EDT
Subject: Re: Orthomolecular Solutions to Heart Disease
Good work, Chris. On vitamin B6 why not add the info from trials:
(1) Thousands of people in East Texas took 50-300 milligrams of B6 daily for many years under the guidance of John Marion Ellis, MD, of Mt. Pleasant, Texas. He urged no change in the lives of patients suffering from carpal tunnel syndrome and osteoarthritis -- those symptoms accurately portray high cardiac risk -- except "Take vitamin B6." Yet a retrospective study found his patients had 73 percent fewer chest pains and heart attacks than thousands of ab-stainers in the same area; they lived seven to 17 years longer; and they felt better. Ellis JM, McCully KS. Prevention of myocardial infarction by vitamin B6. Research Comm Molec Path and Pharmacol 1995; 89; 2:208-220.
(They -- and patients of Moses M. Suzman, MD, using B6 from 1950-1990 -- never complained of over publicized neurological side effects. A few people may be sensitive to this vitamin as pyridoxine hydrochloride, its common supplemented form. Russell Jaffe, MD, PhD, eliminated neurological side effects among thousands of volunteers by using pharmaceutical grade B6, 200 to 2,000 milligrams daily for up to two years. Lecture in Seattle, 1990. The product is available from VRP 1-800-877-2447; 1-702-884-1300 www.vrp.com, and possibly from others.)
(2) Among a sample of women followed for 20 years in the prospective Nurses' Health Study, after adjustment for other risk factors heart attack risk dropped 17 percent for each two-milligram increase in daily B6 consumption in both diet and supplements. Higher intakes yielded lower cardiac risk; an increase of eight milligrams might then lower risk by 68%. Rimm EB, Willett WC et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. Journal American Medical Assoc. 1998; 279; 5:359-364.
(3) In the 10-year ARIC (Atherosclerosis Risk in Communities) study, the people in the highest quintile of plasma vitamin B6 had 72 percent fewer heart attacks than those in the lowest quintile of plasma B6. As in Dr. Ellis's experience, for non-cardiac patients nothing but B6 made any difference in cardiac risk - not even now-famous homocysteine. Folsom AR, Nieto FJ et al. Prospective study of coronary heart disease incidence in relation to fasting total homo-cysteine, related genetic polymorphisms, and B vitamins. Circulation 1998; 98:204-210.
Moses M. Suzman, MD, of Johannesburg, South Africa, earlier confirmed that finding with tens of thousands of patients over a period of forty years but did not publish the results. Hattersley JG. Acquired atherosclerosis: Theories of causation, novel therapies. Jour Orthomolecular Med 1991; 6:83-98. Derived from 50 telephone conversations and a 3-day stay at Dr. Suzman's home in Johannesburg, April 1992, with several interviews.
The findings appear to confirm all the requirements for proof that vitamin B6 prevents heart attacks. Doll, Sir Richard. Proof of causality. Deduction from epidemiological observation. Perspectives Biol Med 2002; 45; 4: 499-515
posted by Chris Gupta on Tuesday June 3 2003
updated on Thursday October 5 2006
URL of this article:
Drinking Water Fluoridation is Genotoxic & Teratogenic
This paper by Prof. Joe Cummins is a very important 5 minute delegation made to London Ontario Canada "Civic Works Committee" public participation meeting on January 25, 2012 on fluoride*. While a bit technical it is short and easy to grasp. A must read as it goes to the heart of the matter regarding the well established toxicity of fluoride which is well in all scientific circles even before water... [read more]
February 06, 2012 - Chris Gupta
Democracy At Work? - PPM On Fluoride
Here is a commentary on the recent (Jan, 25th, 2011) Public Participation Meeting (PPM) on Fluoride in the City of London, Ontario. The meeting started with a strong pro fluoride stance form the City engineer. His lack of knowledge on chemistry of the toxic wastes used to fluoridate water could embarrass even a high school student never mind his own profession. He blatantly violated his "duty to public welfare" as... [read more]
January 29, 2012 - Chris Gupta
"Evidence Be Damned...Patient Outcome Is Irrelevant" - From Helke
Further to The Future of Complementary/Integrative Medicine & Patient Choice, here is an important must read and act note from Helke Ferrie, a superb Medical Science Writer and Publisher. Now that the true colours of the well known shortcomings of allopathic medicine are being discovered en mass, the screws are being tightened by the pharmaceutical masters on their medical puppets. It seems that they are prepared to stop at nothing.... [read more]
September 16, 2011 - Chris Gupta